[Alpha Tau in PR Newswire] Alpha Tau announces receipt of radioactive license to allow production in main manufacturing floor at its Jerusalem site, amended radioactive license with increased capacity at Lawrence, MA site 



JERUSALEM, June 16, 2022 /PRNewswire/ — Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that the Israeli Ministry of Environmental Protection has granted the Company an active radioactive license for use and possession of Thorium-228 and Radium-224, radioactive materials which are utilized in the production of the Alpha DaRT sources, in the main manufacturing floor of the Company’s production facility in Jerusalem.

Read more here.